Merck KGaA agreed to buy Bio-Techne Corporation for $73 per share in cash, valuing the deal at about $11.3 billion. The transaction is a significant strategic acquisition in the healthcare and biotech space and could reshape Merck's portfolio. This is likely to be a sector-moving M&A headline and may support both companies' shares on deal approval expectations.
Merck KGaA agreed to buy Bio-Techne Corporation for $73 per share in cash, valuing the deal at about $11.3 billion. The transaction is a significant strategic acquisition in the healthcare and biotech space and could reshape Merck's portfolio. This is likely to be a sector-moving M&A headline and may support both companies' shares on deal approval expectations.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
moderately positive
Sentiment Score
0.55
Ticker Sentiment
